Kenji Harada

Patient-derived organoids for modeling therapy tolerance, persistence, and resistance in cancer

Therapy resistance remains a major obstacle to durable cancer control. Across cytotoxic chemotherapy, molecularly targeted therapy, immunotherapy, endocrine therapy, and cellular therapy, treatment failure may manifest as primary nonresponse, residual disease, reversible regrowth...